new glp-1 agonists glp 1 agonist In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron What Are GLP-1 Agonists For

and speaking fees from Boehringer Ingelheim and Novo Nordisk Inc

Insomnia is addressable with morning dosing

Which molecule class segment is expected to contribute significant share in the obesity GLP-1 market in 2025

November 1, 2024: Physicians Warn People Taking Ozempic of Skeletal Muscle Mass Loss and Call for More Research Recent commentary published in JAMA warns that skeletal muscle mass (SMM) experienced while taking GLP-1 drugs may be of medical concern

Nonetheless, other research work and metaanalyses have not consistently shown an elevated index of pancreatitis or pancreatic cancer in T2DM subjects who are prescribed DPP4i in comparison to other antidiabetic medications